FR24C1055I2 - Formes cristallines du 6-((6,7-diméthoxyquinazolin-4-yl)oxy)-n,2-diméthylbenzofuran-3-carboxamide - Google Patents

Formes cristallines du 6-((6,7-diméthoxyquinazolin-4-yl)oxy)-n,2-diméthylbenzofuran-3-carboxamide

Info

Publication number
FR24C1055I2
FR24C1055I2 FR24C1055C FR24C1055C FR24C1055I2 FR 24C1055 I2 FR24C1055 I2 FR 24C1055I2 FR 24C1055 C FR24C1055 C FR 24C1055C FR 24C1055 C FR24C1055 C FR 24C1055C FR 24C1055 I2 FR24C1055 I2 FR 24C1055I2
Authority
FR
France
Prior art keywords
dimethoxyquinazolin
dimethylbenzofuran
carboxamide
oxy
crystalline forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1055C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Hutchmed Ltd
Original Assignee
Hutchmed Ltd
Hutchmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55458346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1055(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchmed Ltd, Hutchmed Ltd filed Critical Hutchmed Ltd
Publication of FR24C1055I1 publication Critical patent/FR24C1055I1/fr
Application granted granted Critical
Publication of FR24C1055I2 publication Critical patent/FR24C1055I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR24C1055C 2014-09-10 2024-12-16 Formes cristallines du 6-((6,7-diméthoxyquinazolin-4-yl)oxy)-n,2-diméthylbenzofuran-3-carboxamide Active FR24C1055I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410456350.9A CN105461702A (zh) 2014-09-10 2014-09-10 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
PCT/CN2015/089035 WO2016037550A1 (fr) 2014-09-10 2015-09-07 Formes cristallines du 6-((6,7-diméthoxyquinazolin-4-yl)oxy)-n,2-diméthylbenzofuran-3-carboxamide

Publications (2)

Publication Number Publication Date
FR24C1055I1 FR24C1055I1 (fr) 2025-02-21
FR24C1055I2 true FR24C1055I2 (fr) 2025-10-10

Family

ID=55458346

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1055C Active FR24C1055I2 (fr) 2014-09-10 2024-12-16 Formes cristallines du 6-((6,7-diméthoxyquinazolin-4-yl)oxy)-n,2-diméthylbenzofuran-3-carboxamide

Country Status (35)

Country Link
US (4) US10519142B2 (fr)
EP (1) EP3191475B1 (fr)
JP (2) JP6655608B2 (fr)
KR (2) KR20170042662A (fr)
CN (3) CN105461702A (fr)
AU (1) AU2015316010B2 (fr)
BR (1) BR112017004000B1 (fr)
CA (1) CA2958666C (fr)
CL (1) CL2017000540A1 (fr)
CY (2) CY1123892T1 (fr)
DK (1) DK3191475T3 (fr)
EA (1) EA034730B1 (fr)
ES (1) ES2819242T3 (fr)
FI (1) FIC20240047I1 (fr)
FR (1) FR24C1055I2 (fr)
HR (1) HRP20201501T1 (fr)
HU (2) HUE050580T2 (fr)
IL (1) IL250647B (fr)
LT (2) LT3191475T (fr)
MX (1) MX370791B (fr)
MY (1) MY176618A (fr)
NL (1) NL301307I2 (fr)
NO (1) NO2024061I1 (fr)
PE (1) PE20170661A1 (fr)
PH (1) PH12017500451A1 (fr)
PL (1) PL3191475T3 (fr)
PT (1) PT3191475T (fr)
RS (1) RS60829B1 (fr)
SG (1) SG11201701544UA (fr)
SI (1) SI3191475T1 (fr)
SM (1) SMT202000511T1 (fr)
TW (1) TWI718105B (fr)
UA (1) UA120371C2 (fr)
WO (1) WO2016037550A1 (fr)
ZA (1) ZA201701320B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CN111164085B (zh) 2017-09-29 2023-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
US11236077B2 (en) 2018-03-30 2022-02-01 Hangzhou Solipharma Co., Ltd. Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN113330166B (zh) 2019-03-28 2023-05-05 住友重机械工业株式会社 挖土机
CN113200966B (zh) * 2021-04-06 2022-07-22 深圳大学 一种呋喹替尼衍生物、药物组合物和用途
GB202211142D0 (en) * 2022-07-29 2022-09-14 Macfarlan Smith Ltd Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof
WO2024245409A1 (fr) 2023-06-02 2024-12-05 成都苑东生物制药股份有限公司 Hydrate d'inhibiteur de vegfr, forme cristalline de celui-ci et procédé de préparation associé

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101575333B (zh) * 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型

Also Published As

Publication number Publication date
WO2016037550A1 (fr) 2016-03-17
EA201790275A1 (ru) 2017-10-31
US12600713B2 (en) 2026-04-14
CN111018846A (zh) 2020-04-17
PT3191475T (pt) 2020-09-04
SI3191475T1 (sl) 2021-02-26
CL2017000540A1 (es) 2017-09-15
TWI718105B (zh) 2021-02-11
KR20170042662A (ko) 2017-04-19
PE20170661A1 (es) 2017-05-18
CY1123892T1 (el) 2022-03-24
HK1231479A1 (zh) 2017-12-22
TW201609715A (zh) 2016-03-16
CN105461702A (zh) 2016-04-06
AU2015316010B2 (en) 2018-06-14
US20210276983A1 (en) 2021-09-09
KR20190018056A (ko) 2019-02-20
KR102221722B1 (ko) 2021-03-03
MX370791B (es) 2020-01-08
FIC20240047I1 (fi) 2024-12-17
MX2017002913A (es) 2017-06-06
US20240279208A1 (en) 2024-08-22
IL250647A0 (en) 2017-04-30
CN111018846B (zh) 2023-06-06
UA120371C2 (uk) 2019-11-25
EP3191475A4 (fr) 2018-10-03
EP3191475A1 (fr) 2017-07-19
NO2024061I1 (no) 2024-12-17
NL301307I2 (nl) 2024-12-31
CA2958666C (fr) 2020-10-06
IL250647B (en) 2020-11-30
BR112017004000A2 (pt) 2017-12-05
CN106604919B (zh) 2019-11-15
JP2019065019A (ja) 2019-04-25
US10519142B2 (en) 2019-12-31
EP3191475B1 (fr) 2020-07-29
CA2958666A1 (fr) 2016-03-17
US20200140420A1 (en) 2020-05-07
ZA201701320B (en) 2020-07-29
CY2024038I2 (el) 2026-02-25
AU2015316010A8 (en) 2017-05-11
SMT202000511T1 (it) 2020-11-10
EA034730B1 (ru) 2020-03-13
PL3191475T3 (pl) 2021-01-11
ES2819242T3 (es) 2021-04-15
JP2017526710A (ja) 2017-09-14
MY176618A (en) 2020-08-18
AU2015316010A1 (en) 2017-04-27
NZ729884A (en) 2020-09-25
BR112017004000B1 (pt) 2023-10-24
FR24C1055I1 (fr) 2025-02-21
US20170283399A1 (en) 2017-10-05
JP6655608B2 (ja) 2020-02-26
CY2024038I1 (el) 2026-02-25
HRP20201501T1 (hr) 2020-12-25
DK3191475T3 (da) 2020-09-28
RS60829B1 (sr) 2020-10-30
HUE050580T2 (hu) 2020-12-28
LTPA2024541I1 (fr) 2025-01-10
HUS2400047I1 (hu) 2025-01-28
SG11201701544UA (en) 2017-03-30
LT3191475T (lt) 2020-10-12
US11958838B2 (en) 2024-04-16
CN106604919A (zh) 2017-04-26
PH12017500451A1 (en) 2017-07-31
US11046674B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
FR24C1055I1 (fr) Formes cristallines du 6-((6,7-diméthoxyquinazolin-4-yl)oxy)-n,2-diméthylbenzofuran-3-carboxamide
HUE053819T2 (hu) Ciklikus dinukleotid-vegyületek
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3360864T3 (da) Pyrimidinforbindelse
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
EP3298448A4 (fr) Microscope optogénétique
DK3298027T3 (da) Anthelmintiske depsipeptidforbindelser
EP3506842A4 (fr) Ostéotome
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
EP3227309A4 (fr) Difucosyllactose cristallin
DK3185867T3 (da) Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
LT3597189T (lt) Kristaliniai junginia
EP3454846A4 (fr) Cristaux
BR112017006262A2 (pt) ajuste do comprimento de quadro
EP3372589A4 (fr) Dérivé pyrimidine
EP3467158A4 (fr) Creuset
EP3682742C0 (fr) Caramel à l'allulose
DK3307857T3 (da) Trimethylolpropanestere med lavt flydepunkt
EP3385769A4 (fr) Microscope
IL258039A (en) Crystalline forms
EP3367152A4 (fr) Microscope
DK3143019T3 (da) Krystallinsk form af 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinolin-1-carbonitril
DK3337494T3 (da) Lysobactin til anvendelse til behandling af bovin mastitis